Other languages Biodesix, Inc.

Equities

BDSX

US09075X1081

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
1.53 ^USD	+2.00%		-10.53%	-16.85%

05-21	Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting	CI
05-13	TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting	05-21
Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08
Biodesix, Inc. Reaffirms Revenue Guidance for the Full Year 2024	05-08
Top Midday Decliners	04-05
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center	03-25
Biodesix Announces New Master Collaborative Research Agreement with Memorial Sloan Kettering Cancer Center	03-25
Biodesix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-01
Biodesix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-01
Biodesix, Inc. Provides Revenue Guidance for the Year 2024	03-01
Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method	11-14
Biodesix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
Biodesix, Inc. Provides Revenue Guidance for the Year 2023	11-07
Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer	23-09-07
Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer	23-08-22
Biodesix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023	23-08-07
Biodesix Says Study Evaluating Nodify XL2 Test for Benign Lung Nodules Achieves Primary Endpoint; Shares Rise Pre-Bell	23-07-12
Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules	23-07-12
Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDTÂ® Test by the Center for Medicare and Medicaid Services	23-07-06
Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the VeristratÂ®? Blood-Based Host Immune Classifier	23-06-27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Biodesix, Inc.

Equities

BDSX

US09075X1081

Other languages

Filters